Abstract
Although high-grade serous ovarian cancer (HGSOC) is frequently chemoresponsive, a proportion of patients do not respond to platinum-based chemotherapy at presentation or have progression-free survival (PFS) of less than 6 months. Validated predictive biomarkers of lack of response would enable alternative treatment stratification for these patients and identify novel mechanisms of intrinsic resistance. Our aim was to identify DNA methylation biomarkers of poor response to chemotherapy and demonstrate involvement of the associated gene in platinum drug cell sensitivity. DNA methylation was investigated in independent tumor cohorts using Illumina HumanMethylation arrays and gene expression by Affymetrix arrays and qRT-PCR. The role of Msh homeobox 1 (MSX1) in drug sensitivity was investigated by gene reintroduction and siRNA knockdown of ovarian cancer cell lines. CpG sites at contiguous genomic locations within the MSX1 gene have significantly lower levels of methylation in independent cohorts of HGSOC patients, which recur by 6 months compared with after 12 months (P < 0.05, q < 0.05, n = 78), have poor RECIST response (P < 0.05, q < 0.05, n = 61), and are associated with PFS in an independent cohort (n = 146). A decrease in m...Continue Reading
References
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Markman, W Hoskins
Jan 1, 1989·Genes & Development·R E HillD R Davidson
Oct 6, 2005·Cancer Research·Jens M TeodoridisRobert Brown
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 2, 2010·The Journal of Biological Chemistry·Jing HuangShelley L Berger
Mar 17, 2010·The Journal of Pathology·Ahmed Ashour AhmedJames D Brenton
Jun 22, 2010·BJOG : an International Journal of Obstetrics and Gynaecology·G AdamsJ A Green
Aug 20, 2011·Developmental Cell·Jingqiang WangCory Abate-Shen
May 26, 2012·PloS One·Jingqiang Wang, Cory Abate-Shen
Aug 1, 2012·Biochimie·Alexandre How KitJörg Tost
Sep 1, 2012·British Journal of Cancer·J BorleyS Ghaem-Maghami
Sep 14, 2013·European Journal of Oral Sciences·Xiao-yu FengLi-hong Ge
Nov 15, 2013·Future Oncology·Nicoletta Colombo
Mar 22, 2014·Molecular and Clinical Oncology·Yoshihito YokoyamaHideki Mizunuma
Jul 6, 2014·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Seema BhatlekarBruce M Boman
Sep 13, 2014·EMBO Molecular Medicine·Tuan Zea TanJean Paul Thiery
Sep 26, 2014·Nature Reviews. Cancer·Robert BrownJane Borley
Jan 15, 2015·Epigenetics : Official Journal of the DNA Methylation Society·Clara Serra-JuhéLuis A Pérez-Jurado
Citations
Jun 28, 2016·World Journal of Surgical Oncology·Hongfei GaoYimin Han
Dec 15, 2016·Journal of Cellular Physiology·Ai-Jun SunSen Li
Apr 6, 2018·ELife·Peter L FreddolinoSaeed Tavazoie
Jan 1, 2017·Convergent Science Physical Oncology·Paula CunneaChristina Fotopoulou
Jun 24, 2017·BMC Medicine·Tushar TomarG Bea A Wisman
Aug 10, 2017·Cell Biochemistry and Function·Ya-Lei CaoQin Li
Nov 18, 2018·Clinical Epigenetics·Wenna GuoQiang Wang
Mar 9, 2019·Molecular and Clinical Oncology·Julie L HentzeEstrid V Høgdall
Oct 15, 2019·Frontiers in Cell and Developmental Biology·Alka SinghManisha Sachan
Apr 24, 2020·Cancer Cell International·Tian-Fu LiYing Lin
Sep 25, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James M FlanaganRobert Brown
Jan 10, 2021·Seminars in Cancer Biology·Lei GuoYun Huang
Nov 26, 2020·OncoTargets and Therapy·Linlin YangYudong Wang
Mar 18, 2021·Scientific Reports·Jesus Gonzalez BosquetKimberly K Leslie
Sep 26, 2020·Biochemical Pharmacology·Ying ZhouLushan Yu
Jul 23, 2021·Clinical Epigenetics·Li-Yuan FengLi Li
Aug 22, 2021·Seminars in Cancer Biology·Mohammad Aslam KhanAjay Pratap Singh
Apr 26, 2017·Endocrinología, Diabetes Y Nutrición·Sandra Rodríguez-RoderoEdelmiro Menéndez Torre